Literature DB >> 2743306

Proton-mediated liberation of aldophosphamide from a nontoxic prodrug: a strategy for tumor-selective activation of cytocidal drugs.

L F Tietze1, M Neumann, T Möllers, R Fischer, K H Glüsenkamp, M F Rajewsky, E Jähde.   

Abstract

Based on the findings that the pH in malignant tumors can be preferentially decreased by stimulation of their aerobic glycolysis, acid-sensible prodrugs, which are nearly nontoxic at physiological pH, were synthesized. At lower pH, however, these compounds are cleaved with liberation of a cytotoxic species. The prototypic drug compound 2-hexenopyranoside of aldophosphamide was prepared, which releases aldophosphamide by acid-catalyzed hydrolysis. Exposure of cultured M1R rat mammary carcinoma cells to this agent at pH 7.4 only resulted in slight toxicity. However, when drug treatment was performed at pH 6.2, the mean pH in malignant tumors of hyperglycemic hosts, the colony-forming fraction of M1R cells decreased to 0.05 and 0.0001 of controls treated at pH 7.4 after exposure for 24 h and 48 h, respectively. The synthesis of the 2-hexenopyranoside of aldophosphamide is described in detail.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2743306

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.

Authors:  Stuart Ibsen; Yongxuan Su; John Norton; Eran Zahavy; Tomoko Hayashi; Stephen Adams; Wolf Wrasidlo; Sadik Esener
Journal:  J Mass Spectrom       Date:  2013-07       Impact factor: 1.982

2.  A novel Doxorubicin prodrug with controllable photolysis activation for cancer chemotherapy.

Authors:  Stuart Ibsen; Eran Zahavy; Wolf Wrasdilo; Michael Berns; Michael Chan; Sadik Esener
Journal:  Pharm Res       Date:  2010-07-02       Impact factor: 4.200

3.  Drug Delivery Nanoparticles with Locally Tunable Toxicity Made Entirely from a Light-Activatable Prodrug of Doxorubicin.

Authors:  Carolyn Schutt; Stuart Ibsen; Eran Zahavy; Santosh Aryal; Stacey Kuo; Selin Esener; Michael Berns; Sadik Esener
Journal:  Pharm Res       Date:  2017-08-08       Impact factor: 4.200

4.  Localized in vivo activation of a photoactivatable doxorubicin prodrug in deep tumor tissue.

Authors:  Stuart Ibsen; Eran Zahavy; Wolf Wrasidlo; Tomoko Hayashi; John Norton; Yongxuan Su; Stephen Adams; Sadik Esener
Journal:  Photochem Photobiol       Date:  2013-03-06       Impact factor: 3.421

5.  Development of a tumor-specific photoactivatable doxorubicin prodrug.

Authors:  Albert W Girotti; Giorgio Minotti
Journal:  Photochem Photobiol       Date:  2013-09-03       Impact factor: 3.421

6.  Ruthenium dihydroxybipyridine complexes are tumor activated prodrugs due to low pH and blue light induced ligand release.

Authors:  Kyle T Hufziger; Fathima Shazna Thowfeik; David J Charboneau; Ismael Nieto; William G Dougherty; W Scott Kassel; Timothy J Dudley; Edward J Merino; Elizabeth T Papish; Jared J Paul
Journal:  J Inorg Biochem       Date:  2013-10-14       Impact factor: 4.155

7.  Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).

Authors:  A Kuin; M Aalders; M Lamfers; D J van Zuidam; M Essers; J H Beijnen; L A Smets
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

Review 8.  Microbubble-mediated ultrasound therapy: a review of its potential in cancer treatment.

Authors:  Stuart Ibsen; Carolyn E Schutt; Sadik Esener
Journal:  Drug Des Devel Ther       Date:  2013-05-03       Impact factor: 4.162

9.  pH in human tumour xenografts: effect of intravenous administration of glucose.

Authors:  T Volk; E Jähde; H P Fortmeyer; K H Glüsenkamp; M F Rajewsky
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.